Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.

Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit DB, Klimstra DS, Hyman DM, Taylor BS, Berger MF.

JAMA Oncol. 2019 Nov 14. doi: 10.1001/jamaoncol.2019.3985. [Epub ahead of print]

PMID:
31725847
2.

Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.

Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, Fornier MN.

Clin Breast Cancer. 2018 Oct;18(5):387-394. doi: 10.1016/j.clbc.2018.03.010. Epub 2018 Mar 15.

3.

Canted Antiferromagnetism in Two-Dimensional Silver(II) Bis[pentafluoridooxidotungstate(VI)].

Mazej Z, Gilewski T, Goreshnik EA, Jagličić Z, Derzsi M, Grochala W.

Inorg Chem. 2017 Jan 3;56(1):224-233. doi: 10.1021/acs.inorgchem.6b02034. Epub 2016 Dec 19.

PMID:
27991784
4.

[Ag(OH2 )2 ][Ag(SO4 )2 ]: A Hydrate of a Silver(II) Salt.

Gilewski TE, Gawraczyński J, Derzsi M, Jagličić Z, Mazej Z, Połczyński P, Jurczakowski R, Leszczyński PJ, Grochala W.

Chemistry. 2017 Feb 3;23(8):1805-1813. doi: 10.1002/chem.201604179. Epub 2016 Dec 19.

PMID:
27862472
5.

Ag2S2O8 meets AgSO4: the second example of metal-ligand redox isomerism among inorganic systems.

Gilewski TE, Leszczyński PJ, Budzianowski A, Mazej Z, Grzelak A, Jaroń T, Grochala W.

Dalton Trans. 2016 Nov 15;45(45):18202-18207.

PMID:
27796396
6.

The Complexities of Compassion in Patient Care.

Gilewski T.

JAMA Oncol. 2015 May;1(2):183-4. doi: 10.1001/jamaoncol.2014.296. No abstract available.

PMID:
26181020
7.

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C.

J Clin Oncol. 2015 Feb 10;33(5):442-7. doi: 10.1200/JCO.2014.57.1745. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):354.

8.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S.

Clin Breast Cancer. 2014 Jun;14(3):154-60. doi: 10.1016/j.clbc.2013.12.012. Epub 2013 Dec 28.

PMID:
24512858
9.

The joys and challenges of caring for patients.

Gilewski T.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e327. Review.

10.

Encountering grief in patient care.

Gilewski T.

Am Soc Clin Oncol Educ Book. 2012:e81-4. doi: 10.14694/EdBook_AM.2012.32.e81.

PMID:
24451837
11.

The oncologist as the patient with cancer or relative.

Gilewski T, Raber M, Sledge GW.

Am Soc Clin Oncol Educ Book. 2012:561-3. doi: 10.14694/EdBook_AM.2012.32.561.

PMID:
24451796
12.

A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.

Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA.

Ann Oncol. 2011 Dec;22(12):2575-81. doi: 10.1093/annonc/mdr018. Epub 2011 Mar 15.

13.

A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN.

Clin Cancer Res. 2011 May 15;17(10):3398-407. doi: 10.1158/1078-0432.CCR-10-1969. Epub 2011 Feb 24.

14.

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.

Drullinsky P, Sugarman SM, Fornier MN, D'Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C.

Clin Breast Cancer. 2010 Dec 1;10(6):440-4. doi: 10.3816/CBC.2010.n.057.

15.

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.

Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA.

Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141.

16.

Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.

Dang C, D'Andrea G, Lake D, Sugarman S, Fornier M, Moynahan ME, Gilewski T, Hurria A, Mills N, Troso-Sandoval T, George R, Robson M, Dickler M, Smith K, Panageas KS, Norton L, Hudis CA.

Clin Breast Cancer. 2008 Oct;8(5):418-24. doi: 10.3816/CBC.2008.n.050.

PMID:
18952555
17.

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C.

J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733.

PMID:
18323546
18.

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO.

Clin Cancer Res. 2007 May 15;13(10):2977-85.

19.

Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.

Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO.

Int J Cancer. 2002 Feb 10;97(5):660-7.

20.

A piece of my mind: the subtle power of compassion.

Gilewski T.

JAMA. 2001 Dec 26;286(24):3052-3. No abstract available.

PMID:
11754649
21.

Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.

Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C.

Clin Cancer Res. 2001 Dec;7(12):3934-41.

22.

The art of medicine: teaching oncology fellows about the end of life.

Gilewski T.

Crit Rev Oncol Hematol. 2001 Nov;40(2):105-13. Review.

PMID:
11682317
23.

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA.

J Clin Oncol. 2001 May 15;19(10):2587-95.

PMID:
11352950
24.

Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial.

Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3270-5. Erratum in: Proc Natl Acad Sci U S A 2001 Nov 20;98(24):14186.

25.

Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.

Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ.

J Clin Oncol. 2000 Oct 15;18(20):3459-63.

PMID:
11032585
26.

An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel. Breast Cancer Medicine Service.

Gilewski T, Seidman A, Norton L, Hudis C.

Cancer Chemother Pharmacol. 2000;46 Suppl:S23-6. Review.

PMID:
10950143
27.

Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO.

Clin Cancer Res. 2000 May;6(5):1693-701.

28.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L.

J Clin Oncol. 1999 Apr;17(4):1118.

PMID:
10561169
29.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L.

J Clin Oncol. 1999 Jan;17(1):93-100.

PMID:
10458222
30.

Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.

Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G, Livingston P.

Br J Cancer. 1999 Apr;79(11-12):1806-12.

31.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.

Clin Cancer Res. 1999 Feb;5(2):275-9.

32.

BRCA-associated breast cancer in young women.

Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K.

J Clin Oncol. 1998 May;16(5):1642-9.

PMID:
9586873
33.

BRCA-associated breast cancer: absence of a characteristic immunophenotype.

Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K.

Cancer Res. 1998 May 1;58(9):1839-42.

34.

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L.

Cancer Invest. 1998;16(2):67-71. No abstract available.

PMID:
9512671
35.

Phase II study of semisynthetic paclitaxel in metastatic breast cancer.

Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L.

Eur J Cancer. 1997 Nov;33(13):2198-202.

PMID:
9470806
36.

Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.

Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, Osborne M, Norton L, Gilbert F, Offit K.

Genet Test. 1997;1(1):47-51.

PMID:
10464625
37.

Germline BRCA1 185delAG mutations in Jewish women with breast cancer.

Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, Swensen J, Neuhausen S, Skolnick M, Norton L, Goldgar D.

Lancet. 1996 Jun 15;347(9016):1643-5.

PMID:
8642955
38.

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L.

J Clin Oncol. 1996 Jun;14(6):1877-84.

PMID:
8656256
39.

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K.

Nat Genet. 1996 May;13(1):126-8.

PMID:
8673092
40.

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L.

Semin Oncol. 1996 Feb;23(1 Suppl 1):58-64.

PMID:
8629040
41.

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L.

J Clin Oncol. 1996 Jan;14(1):58-65.

PMID:
8558221
42.

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al.

Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.

PMID:
8643965
43.

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, et al.

J Clin Oncol. 1995 Oct;13(10):2575-81.

PMID:
7595709
44.

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, et al.

J Clin Oncol. 1995 May;13(5):1152-9.

PMID:
7537798
45.

Conditioned emotional distress in women receiving chemotherapy for breast cancer.

Jacobsen PB, Bovbjerg DH, Schwartz MD, Hudis CA, Gilewski TA, Norton L.

J Consult Clin Psychol. 1995 Feb;63(1):108-14.

PMID:
7896975
46.

Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.

Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Hudis CA, Surbone A, et al.

Oncology. 1994 Oct;51 Suppl 1:33-9.

PMID:
7526308
47.

Taxol and recombinant human granulocyte colony-stimulating factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary report.

Reichman BS, Seidman AD, Crown JP, Heelan R, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, et al.

Ann N Y Acad Sci. 1993 Nov 30;698:398-402. No abstract available.

PMID:
7506506
48.

High-intensity chemotherapy with hematopoietic support in breast cancer.

Crown J, Vahdat L, Fennelly D, Francis P, Wasserheit C, Hudis C, Kritz A, Schneider J, Hamilton N, Gilewski T, et al.

Ann N Y Acad Sci. 1993 Nov 30;698:378-88. Review.

PMID:
7506505
49.

Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy.

Jacobsen PB, Bovbjerg DH, Schwartz MD, Andrykowski MA, Futterman AD, Gilewski T, Norton L, Redd WH.

Behav Res Ther. 1993 Nov;31(8):739-48.

PMID:
8257405
50.

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, et al.

J Clin Oncol. 1993 Oct;11(10):1943-51.

PMID:
7691998

Supplemental Content

Loading ...
Support Center